JP2021506243A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021506243A5 JP2021506243A5 JP2020531949A JP2020531949A JP2021506243A5 JP 2021506243 A5 JP2021506243 A5 JP 2021506243A5 JP 2020531949 A JP2020531949 A JP 2020531949A JP 2020531949 A JP2020531949 A JP 2020531949A JP 2021506243 A5 JP2021506243 A5 JP 2021506243A5
- Authority
- JP
- Japan
- Prior art keywords
- cell line
- immortalized
- cell
- seq
- domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762598032P | 2017-12-13 | 2017-12-13 | |
| US62/598,032 | 2017-12-13 | ||
| PCT/US2018/064971 WO2019118475A1 (en) | 2017-12-13 | 2018-12-11 | Immortalized car-t cells genetically modified to eliminate t-cell receptor and beta 2-microglobulin expression |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021506243A JP2021506243A (ja) | 2021-02-22 |
| JP2021506243A5 true JP2021506243A5 (https=) | 2022-01-11 |
Family
ID=66734891
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020531949A Pending JP2021506243A (ja) | 2017-12-13 | 2018-12-11 | Ｔ細胞受容体及びβ２ミクログロブリン発現を排除するように遺伝子改変された不死化ＣＡＲ−Ｔ細胞 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20200332255A1 (https=) |
| EP (1) | EP3724321A4 (https=) |
| JP (1) | JP2021506243A (https=) |
| KR (1) | KR20200088383A (https=) |
| CN (1) | CN111479917A (https=) |
| AU (1) | AU2018386010A1 (https=) |
| CA (1) | CA3082204A1 (https=) |
| SG (1) | SG11202003864XA (https=) |
| WO (1) | WO2019118475A1 (https=) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10704021B2 (en) | 2012-03-15 | 2020-07-07 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
| WO2015105955A1 (en) | 2014-01-08 | 2015-07-16 | Flodesign Sonics, Inc. | Acoustophoresis device with dual acoustophoretic chamber |
| US11708572B2 (en) | 2015-04-29 | 2023-07-25 | Flodesign Sonics, Inc. | Acoustic cell separation techniques and processes |
| US11377651B2 (en) | 2016-10-19 | 2022-07-05 | Flodesign Sonics, Inc. | Cell therapy processes utilizing acoustophoresis |
| WO2018111976A1 (en) | 2016-12-14 | 2018-06-21 | Janssen Biotech, Inc. | Pd-l1 binding fibronectin type iii domains |
| NZ754187A (en) | 2016-12-14 | 2026-02-27 | Janssen Biotech Inc | Cd8a-binding fibronectin type iii domains |
| US10611823B2 (en) | 2016-12-14 | 2020-04-07 | Hanssen Biotech, Inc | CD137 binding fibronectin type III domains |
| BR112019018915A2 (pt) | 2017-03-15 | 2020-04-14 | Pandion Therapeutics Inc | imunotolerância direcionada |
| JP2020521452A (ja) | 2017-05-24 | 2020-07-27 | パンディオン・セラピューティクス・インコーポレイテッド | 標的化免疫寛容 |
| WO2019018402A2 (en) * | 2017-07-17 | 2019-01-24 | Janssen Biotech, Inc. | ANTIGEN-BINDING REGIONS DIRECTED AGAINST FIBRONECTIN TYPE III DOMAINS AND METHODS OF USING THE SAME |
| US10174091B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
| US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| USRE50550E1 (en) | 2017-12-06 | 2025-08-26 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| WO2020236875A1 (en) | 2019-05-20 | 2020-11-26 | Pandion Therapeutics, Inc. | Madcam targeted immunotolerance |
| BR112022001331A2 (pt) | 2019-07-26 | 2022-06-14 | Janssen Biotech Inc | Receptor quimérico de antígeno (car) anti-hk2 |
| US12344656B2 (en) | 2019-09-06 | 2025-07-01 | Crispr Therapeutics Ag | Genetically engineered T cells having improved persistence in culture |
| WO2021076543A1 (en) * | 2019-10-14 | 2021-04-22 | Aro Biotherapeutics Company | Epcam binding fibronectin type iii domains |
| CN114786682B (zh) | 2019-10-14 | 2024-07-16 | Aro生物疗法公司 | 结合cd71的纤维粘连蛋白iii型结构域 |
| WO2021076574A2 (en) | 2019-10-14 | 2021-04-22 | Aro Biotherapeutics Company | Fn3 domain-sirna conjugates and uses thereof |
| US11981715B2 (en) | 2020-02-21 | 2024-05-14 | Pandion Operations, Inc. | Tissue targeted immunotolerance with a CD39 effector |
| US11591381B2 (en) | 2020-11-30 | 2023-02-28 | Crispr Therapeutics Ag | Gene-edited natural killer cells |
| AU2021392032A1 (en) | 2020-12-03 | 2023-06-22 | Century Therapeutics, Inc. | Genetically engineered cells and uses thereof |
| US11661459B2 (en) | 2020-12-03 | 2023-05-30 | Century Therapeutics, Inc. | Artificial cell death polypeptide for chimeric antigen receptor and uses thereof |
| WO2022144632A1 (en) | 2020-12-30 | 2022-07-07 | Crispr Therapeutics Ag | Compositions and methods for differentiating stem cells into nk cells |
| BR112023021318A2 (pt) | 2021-04-14 | 2023-12-19 | Aro Biotherapeutics Company | Conjugados de domínio fn3-sirna e usos dos mesmos |
| CA3214552A1 (en) * | 2021-04-14 | 2022-10-20 | Russell C. Addis | Cd71 binding fibronectin type iii domains |
| WO2022250431A1 (ko) * | 2021-05-25 | 2022-12-01 | 주식회사 박셀바이오 | 모노바디 기반 키메라 항원 수용체 및 이를 포함하는 면역 세포 |
| US20230190809A1 (en) * | 2021-09-10 | 2023-06-22 | Tmunity Therapeutics Inc. | Alternative generation of allogeneic human t cells |
| CN116023496B (zh) * | 2021-10-27 | 2026-02-27 | 菲鹏弘济生物(深圳)有限公司 | 一种制备通用型car-t细胞的方法及其应用 |
| US12006353B2 (en) | 2022-07-25 | 2024-06-11 | Long Chen | Application of SCFV protein, car gene expression vector, CAR-T cell and application thereof |
| JP2026506126A (ja) * | 2023-02-17 | 2026-02-20 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 既製の細胞療法のための多能性幹細胞操作免疫細胞 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2761066B1 (en) * | 2011-09-27 | 2018-12-05 | Janssen Biotech, Inc. | Fibronectin type iii repeat based protein scaffolds with alternative binding surfaces |
| MX373460B (es) * | 2014-03-11 | 2020-04-07 | Cellectis | Metodo para generar celulas t compatibles para el trasplante alogenico. |
| TWI750110B (zh) * | 2014-07-21 | 2021-12-21 | 瑞士商諾華公司 | 使用人類化抗-ｂｃｍａ嵌合抗原受體治療癌症 |
| WO2016069282A1 (en) * | 2014-10-31 | 2016-05-06 | The Trustees Of The University Of Pennsylvania | Altering gene expression in modified t cells and uses thereof |
| EP3292222B1 (en) * | 2015-05-06 | 2025-09-03 | Janssen Biotech, Inc. | Prostate specific membrane antigen binding fibronectin type iii domains |
| IL297018A (en) * | 2015-12-18 | 2022-12-01 | Sangamo Therapeutics Inc | Directed cleavage of cell mhc receptor |
| AU2016369490C1 (en) * | 2015-12-18 | 2021-12-23 | Sangamo Therapeutics, Inc. | Targeted disruption of the T cell receptor |
| EP3988655A3 (en) * | 2015-12-23 | 2022-08-03 | Precision Biosciences, Inc. | Engineered meganucleases with recognition sequences found in the human beta-2 microglobulin gene |
| MA46236A (fr) * | 2016-09-14 | 2019-07-24 | Janssen Biotech Inc | Récepteurs antigéniques chimériques comprenant des domaines de la fibronectine de type iii spécifiques du bcma, et utilisations correspondantes |
-
2018
- 2018-12-11 CN CN201880080452.1A patent/CN111479917A/zh active Pending
- 2018-12-11 AU AU2018386010A patent/AU2018386010A1/en not_active Abandoned
- 2018-12-11 JP JP2020531949A patent/JP2021506243A/ja active Pending
- 2018-12-11 SG SG11202003864XA patent/SG11202003864XA/en unknown
- 2018-12-11 CA CA3082204A patent/CA3082204A1/en active Pending
- 2018-12-11 WO PCT/US2018/064971 patent/WO2019118475A1/en not_active Ceased
- 2018-12-11 KR KR1020207016631A patent/KR20200088383A/ko not_active Ceased
- 2018-12-11 US US16/770,809 patent/US20200332255A1/en not_active Abandoned
- 2018-12-11 EP EP18888643.6A patent/EP3724321A4/en not_active Withdrawn
- 2018-12-11 US US16/215,716 patent/US20190175651A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021506243A5 (https=) | ||
| JP7306731B2 (ja) | ソルターゼ（Ｓｏｒｔａｓｅ）を用いた生存細胞のタンパク質修飾 | |
| Siemaszko et al. | NKG2D natural killer cell receptor—a short description and potential clinical applications | |
| JP7416695B2 (ja) | 増強されたキメラ抗原受容体およびその使用 | |
| JP7783746B2 (ja) | 操作されたｉＰＳＣおよび免疫エフェクター細胞におけるＣＤ３の再構成 | |
| CN106103475B (zh) | 产生同种异体移植相容的t细胞的方法 | |
| Imamura et al. | Induction of primordial germ cells from mouse induced pluripotent stem cells derived from adult hepatocytes | |
| CN114729315B (zh) | 用于提供具有增强功能的免疫细胞的方法 | |
| JP2021505131A (ja) | 増強されたｉＰＳＣ由来のエフェクター細胞を用いた免疫療法 | |
| JP2021506236A (ja) | 強化された免疫エフェクター細胞およびその使用 | |
| JP2021519061A (ja) | 操作された免疫エフェクター細胞およびその使用 | |
| CN114761425A (zh) | 用于免疫效应细胞工程化的增强的嵌合抗原受体和其用途 | |
| JP2017529851A5 (https=) | ||
| CN114901693A (zh) | 用于免疫效应细胞工程化的增强的嵌合抗原受体和其用途 | |
| JP2020509050A5 (https=) | ||
| WO2018205926A1 (zh) | 经修饰的t细胞、其制备方法及用途 | |
| JP2016534717A5 (https=) | ||
| JP2019530431A5 (https=) | ||
| JP2024537991A (ja) | 共発現されるｓｈＲＮＡと論理ゲートシステムとを有する免疫細胞 | |
| BR112020020919A2 (pt) | Receptor de antígeno quimérico específico para receptor de interleucina-23 | |
| IL302476A (en) | Engineered ipsc and immune effector cells for heterogenous tumor control | |
| WO2022063302A1 (zh) | 免疫细胞活性调节 | |
| CA3196555A1 (en) | Multiplexed engineered ipsc and immune effector cells targeting solid tumors | |
| CN113631184A (zh) | 通过抑制ebag9增强溶细胞性t细胞活性 | |
| IL301983A (en) | Transgenic induced pluripotent stem cells and effector carrier cells of the immune system |